PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (Nasdaq:ANAC), today announced the sale of 3.25 million shares of its common stock for gross proceeds of $21,450,000 pursuant to an underwriting agreement with Canaccord Genuity acting as the sole bookrunner. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 487,500 shares of common stock to cover over-allotments, if any.
